Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04675710 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer

A Phase 2 study of Thyroid Gland Anaplastic Carcinoma and Thyroid Gland Squamous Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
30
Enrollment target
6
Study locations

NCT04675710 is a Phase 2 study of Thyroid Gland Anaplastic Carcinoma and Thyroid Gland Squamous Cell Carcinoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 30 participants, roughly in line with the 29-participant average among 3 other Thyroid Gland Anaplastic Carcinoma trials with a reported enrollment target. The trial reports 6 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04675710, a Phase 2 study of Thyroid Gland Anaplastic Carcinoma and Thyroid Gland Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
30 participants
Enrollment target
6
Study locations

Study Summary

This phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer. BRAF V600E is a specific mutation (change) in the BRAF gene, which makes a protein that is involved in sending signals in cells and in cell growth. It may increase the growth and spread of tumor cells. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pembrolizumab, dabrafenib, and trametinib may help to control BRAF V600E-mutated anaplastic thyroid cancer when given before surgery.

Conditions Studied

Thyroid Gland Anaplastic Carcinoma Thyroid Gland Squamous Cell Carcinoma

Interventions

  • BIOLOGICAL Pembrolizumab
  • OTHER Quality-of-Life Assessment
  • RADIATION Intensity-Modulated Radiation Therapy
  • PROCEDURE Conventional Surgery
  • DRUG Dabrafenib

Study Locations (6)

California

  • Stanford School of Medicine - Stanford

Michigan

  • University of Michigan Rogel Cancer Center - Ann Arbor

Minnesota

  • Mayo Clinic - Rochester

Ohio

  • Cleveland Clinic Taussig Cancer Institute - Cleveland

Texas

  • M D Anderson Cancer Center - Houston

Utah

  • Huntsman Cancer Institute at the University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2021-06-24
Est. Completion 2026-10-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04675710

The ClinicalTrials.gov registry entry for NCT04675710 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 29-participant average among 3 other Thyroid Gland Anaplastic Carcinoma trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Thyroid Gland Anaplastic Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT04675710 reports 6 study locations spanning 6 distinct geographic areas - top geographies include California, Michigan, Minnesota.

Frequently Asked Questions

What is clinical trial NCT04675710 about?

NCT04675710 is a clinical study titled "Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer". This phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer. BRAF V600E is a specific mutation (change) in the BRAF gene, which makes a protein that is involved in sending signals in cells a...

What is the current status of trial NCT04675710?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-06-24. Estimated completion is 2026-10-30.

What conditions does trial NCT04675710 study?

This clinical trial studies the following conditions: Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma.

What interventions are being tested in trial NCT04675710?

The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Quality-of-Life Assessment (OTHER), Intensity-Modulated Radiation Therapy (RADIATION), Conventional Surgery (PROCEDURE), Dabrafenib (DRUG).

Who is sponsoring clinical trial NCT04675710?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04675710 being conducted?

This trial has 6 study locations across California, Michigan, Minnesota, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Gland Anaplastic Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thyroid Gland Anaplastic Carcinoma

All registered trials for this condition

Thyroid Gland Squamous Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.